Eli Lilly Breaks Ground on $6.5B Houston Manufacturing Plant
McCord Development beat more than 300 competing site proposals to land it, a playbook other industrial landowners are now racing to copy.
Eli Lilly broke ground September 21 on a $6.5 billion pharmaceutical manufacturing plant in Northeast Houston’s Generation Park, the company said, calling it the largest active pharmaceutical ingredient project in Texas history. The Houston site is the fifth of ten U.S. manufacturing locations Lilly has announced since 2020 to produce API domestically, part of the company’s broader push to reshore drug production. Landowner McCord Development sold Lilly roughly 236 acres inside the 4,300-acre master-planned park.
Why it matters
This is a site-selection story as much as a pharma story. McCord fielded more than 300 competing proposals nationally before Lilly picked Generation Park, and the deciding factors were not incentives alone: McCord had already sunk $250 million into infrastructure at the park, the site sits outside Houston city limits in its extraterritorial jurisdiction where permitting moves faster, and a biotechnology training center McCord built after losing an Amgen project in 2021 gave Lilly a workforce pipeline already on the ground. For industrial developers chasing megaproject tenants, that is a replicable sequence: pre-invest in infrastructure and permitting speed, build the training pipeline before the tenant asks for it, and control enough contiguous acreage to say yes fast. The Houston market, already stacked with data center and life-sciences megaprojects, is where that playbook is being tested hardest.
The numbers
Lilly’s release puts the investment at $6.5 billion, generating more than 4,000 construction jobs during buildout and 600-plus permanent positions once operating, including engineers, scientists and lab technicians. Lilly is also putting $12.5 million into a training partnership with nearby San Jacinto College and donating $2.5 million for student scholarships there. Neither Lilly’s release nor Bisnow’s coverage discloses a building square footage or a targeted completion or production-start date. Governor Greg Abbott called it “the largest active pharmaceutical ingredient project in Texas history.”
What’s next
Watch whether Lilly discloses a completion timeline or building square footage as construction proceeds, and whether McCord’s infrastructure-first, permitting-friendly formula pulls another marquee manufacturing tenant into Generation Park’s remaining acreage. Five of Lilly’s ten reshoring sites now make API domestically; the other five converting existing or new sites to that use, if any do, would be the next signal of how far the pharma reshoring build wave extends into new industrial construction versus retrofits.